Overview
Dr. Raymond Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute.Dr. Mak received his undergraduate degree from Cornell University and medical degree from Harvard Medical School, trained at the Harvard Radiation Oncology Residency Program, and is board certified in Radiation Oncology.Dr. Mak has over 10 years of experience in radiation treatment of thoracic malignancies including lung cancer, mesothelioma, and thymomas, and in the clinical application of advanced radiation therapy techniques including stereotactic body radiation therapy. He has applied stereotactic body radiation therapy for novel indications including the treatment of cardiac arrhythmias. He led the implementation of MR-guided radiation therapy and adaptive radiation therapy program at BWH/DFCI in 2019 and has expertise in these innovative new treatment approaches. His research interests focus on developing genomic and imaging biomarkers to predict radiation therapy response and toxicity for lung cancer patients, and applying artificial intelligence techniques to automate radiation therapy planning and improve patient care. He has expertise in developing new methods to reduce the risk of cardiac and pulmonary toxicity for patients receiving radiation therapy.
Dr. Mak is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.
His clinical research consists of co-authoring 177 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 72 articles and participated in 1 clinical trial in the study of Non-Small Cell Lung Cancer (NSCLC).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- HMO
Locations
75 Francis Street, Boston, MA 02115
450 Brookline Avenue, Boston, MA 02115
450 Brookline Avenue, Boston, MA 02115
Additional Areas of Focus
Dr. Mak has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Dana-Farber Cancer Institute, Inc.
David Kozono is a Radiation Oncologist in Boston, Massachusetts. Dr. Kozono is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.
The General Hospital Corporation
Henning Willers is a Radiation Oncologist in Boston, Massachusetts. Dr. Willers is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Willers is currently accepting new patients.
Massachusetts General Physicians Organization Inc
Florence Keane is a Radiation Oncologist in Boston, Massachusetts. Dr. Keane is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Pancreaticoduodenectomy. Dr. Keane is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Lung CancerDr. Mak isElite. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Distinguished
- ALK-Positive Non-Small Cell Lung Cancer
- EGFR Positive Lung CancerDr. Mak isDistinguished. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Mak isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Mak isDistinguished. Learn about Lung Adenocarcinoma.
- MesotheliomaDr. Mak isDistinguished. Learn about Mesothelioma.
- Metastatic Pleural TumorDr. Mak isDistinguished. Learn about Metastatic Pleural Tumor.
- Advanced
- Familial Pancreatic CancerDr. Mak isAdvanced. Learn about Familial Pancreatic Cancer.
- Metastatic Brain TumorDr. Mak isAdvanced. Learn about Metastatic Brain Tumor.
- Pancreatic CancerDr. Mak isAdvanced. Learn about Pancreatic Cancer.
- Posterior Fossa TumorDr. Mak isAdvanced. Learn about Posterior Fossa Tumor.
- Primitive Neuroectodermal Tumor (PNET)
- Experienced
- Adenoid Cystic CarcinomaDr. Mak isExperienced. Learn about Adenoid Cystic Carcinoma.
- Adrenocortical CarcinomaDr. Mak isExperienced. Learn about Adrenocortical Carcinoma.
- Adult Soft Tissue SarcomaDr. Mak isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Alveolar Soft Part SarcomaDr. Mak isExperienced. Learn about Alveolar Soft Part Sarcoma.
- Bone TumorDr. Mak isExperienced. Learn about Bone Tumor.
- Brain TumorDr. Mak isExperienced. Learn about Brain Tumor.